Evaluation of factors related to late recurrence - Later than 10 years after the initial treatment - In primary breast cancer

Oncology (Switzerland)

Volumn 85, Issue 2, 2013, Pages 100-110

  Nishimura, Reiki ^a   Osako, Tomofumi ^a   Nishiyama, Yasuyuki ^a   Tashima, Rumiko ^a   Nakano, Masahiro ^a   Fujisue, Mamiko ^a   Toyozumi, Yasuo ^a   Arima, Nobuyuki ^a  

^a KUMAMOTO CITY HOSPITAL   (Japan)

Author keywords

Breast cancer; Estrogen receptor; Ki 67; Late recurrence; Progesterone receptor

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER THERAPY; DISEASE FREE SURVIVAL; EVALUATION STUDY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE;

EID: 84880181816     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000353099     Document Type: Article

References (26)

1. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
2. The Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
3. Goldhirsch A, Wood WC, Coates AS, et al: Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.
4. Saphner T, Tormey DC, Gray R: Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996; 14: 2738-2746.
5. Anderson WF, Chen BE, Jatoi I, Rosenberg PS: Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res Treat 2006; 100: 121-126.
6. Goss PE: Letrozole in the extended adjuvant setting: MA.17. Breast Cancer Res Treat 2007; 105: 45-53.
7. Davies C, Pan H, Godwin J, et al: Long-term effects of continuing adjuvant tamoxifen to years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2012; 736: 61963-61971.
8. Nishimura R, Osako T, Okumura Y, et al: Ki-As a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med 2010; 1: 747-754.
9. Kai K, Nishimura R, Arima N, et al: p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study. Int J Clin Oncol 2006; 11: 426-433.
10. Wolff AC, Hammond MEH, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 18-43.
11. Taktak AF, Eleuteri A, Lake SP, Fisher AC: A web-based tool for the assessment of discrimination and calibration properties of prognostic models. Comput Biol Med 2008; 38: 785-791.
12. Harrell FE Jr, Califf RM, Pryor DB, et al: Evaluating the yield of medical tests. JAMA 1982; 247: 2543-2546.
13. Esserman LJ, Moore DH, Tsing PJ, et al: Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat 2011; 129: 607-616.
14. Cheang MCU, Voduc D, Bajdik C, et al: Basallike breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14: 1368-1376.
15. Demicheli R, Miceli R, Moliterni A, et al: Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol 2005; 16: 1449-1457.
16. Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295: 1658-1667.
17. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-Analysis of randomised trials. Lancet 2011; 378: 771-784.
18. Nishimura R, Osako T, Okumura Y, et al: Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World J Surg Oncol 2011; 9: 131-137.
19. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV: Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005; 23: 7721-7735.
20. Liu S, Chia SK, Mehl E, et al: Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat 2010; 119: 53-61.
21. Osborne CK, Shou J, Massarweh S, Schiff R: Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005; 11: 865s-870s.
22. Prat A, Cheang MCU, Martín M, et al: Prognostic significance of progesterone receptorpositive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 2012; 31: 203-209.
23. Banys M, Hartkopf AD, Krawczyk N, et al: Dormancy in breast cancer. Breast Cancer Targets Ther 2012; 4: 183-191.
24. Meng S, Tripathy D, Frenkel EP, et al: Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004; 10: 8152-8162.
25. Naumov GN, MacDonald IC, Weinmeister PM, et al: Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res 2002; 62: 2162-2168.
26. Fehm T, Krawczyk N, Solomayer EF, et al: ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res 2008; 10:R76.